Live cell pool and rare cell isolation using Enrich TROVO system
N Biotechnol. 2024 Jan 2;80:12-20. doi: 10.1016/j.nbt.2023.12.013. Online ahead of print.ABSTRACTAlthough several technologies have been developed to isolate cells of interest from a heterogenous sample, clogging and impaired cell viability limit such isolation. We have developed the Enrich TROVO system as a novel, nonfluidic technology to sort live cells. The TROVO system combines imaging-based cell selection and photo-crosslinking of (gelatin methacrylate) gelMA-hydrogel to capture cells. After capture, cells are released by enzymatic digestion of the hydrogel and then retrieved for downstream analysis or further cell cu...
Source: New Biotechnology - January 4, 2024 Category: Biotechnology Authors: Stephen Rotatori Yichong Zhang Kirby Madden-Hennessey Christina Mohammed Chi-Han Yang Jordan Urbani Prem Shrestha Joseph Pettinelli Dong Wang Xueqi Liu Qi Zhao Source Type: research
Live cell pool and rare cell isolation using Enrich TROVO system
N Biotechnol. 2024 Jan 2:S1871-6784(23)00081-X. doi: 10.1016/j.nbt.2023.12.013. Online ahead of print.ABSTRACTAlthough several technologies have been developed to isolate cells of interest from a heterogenous sample, clogging and impaired cell viability limit such isolation. We have developed the Enrich TROVO system as a novel, nonfluidic technology to sort live cells. The TROVO system combines imaging-based cell selection and photo-crosslinking of (gelatin methacrylate) gelMA-hydrogel to capture cells. After capture, cells are released by enzymatic digestion of the hydrogel and then retrieved for downstream analysis or fu...
Source: New Biotechnology - January 4, 2024 Category: Biotechnology Authors: Stephen Rotatori Yichong Zhang Kirby Madden-Hennessey Christina Mohammed Chi-Han Yang Jordan Urbani Prem Shrestha Joseph Pettinelli Dong Wang Xueqi Liu Qi Zhao Source Type: research
Novel β-galactosidase activity and first crystal structure of Glycoside Hydrolase family 154
This study focuses on BD-β-Gal, an enzyme encoded in a metagenomic PUL and member of the Glycoside Hydrolase family 154 (GH154). BD-β-Gal showed exo-β-galactosidase activity with regiopreference for hydrolyzing β-d-(1,6) glycosidic linkages. Notably, it exhibited a preference for d-glucopyranosyl (d-Glcp) over d-galactopyranosyl (d-Galp) and d-fructofuranosyl (d-Fruf) at the reducing end of the investigated disaccharides. In addition, we determined the high resolution crystal structure of BD-β-Gal, thus providing the first structural characterization of a GH154 enzyme. Surprisingly, this revealed an (α/α)6 topology,...
Source: New Biotechnology - January 1, 2024 Category: Biotechnology Authors: Lisanne Hameleers Tjaard Pijning Brandon B Gray R égis Fauré Edita Jurak Source Type: research
Novel β-galactosidase activity and first crystal structure of Glycoside Hydrolase family 154
This study focuses on BD-β-Gal, an enzyme encoded in a metagenomic PUL and member of the Glycoside Hydrolase family 154 (GH154). BD-β-Gal showed exo-β-galactosidase activity with regiopreference for hydrolyzing β-d-(1,6) glycosidic linkages. Notably, it exhibited a preference for d-glucopyranosyl (d-Glcp) over d-galactopyranosyl (d-Galp) and d-fructofuranosyl (d-Fruf) at the reducing end of the investigated disaccharides. In addition, we determined the high resolution crystal structure of BD-β-Gal, thus providing the first structural characterization of a GH154 enzyme. Surprisingly, this revealed an (α/α)6 topology,...
Source: New Biotechnology - January 1, 2024 Category: Biotechnology Authors: Lisanne Hameleers Tjaard Pijning Brandon B Gray R égis Fauré Edita Jurak Source Type: research
Novel β-galactosidase activity and first crystal structure of Glycoside Hydrolase family 154
This study focuses on BD-β-Gal, an enzyme encoded in a metagenomic PUL and member of the Glycoside Hydrolase family 154 (GH154). BD-β-Gal showed exo-β-galactosidase activity with regiopreference for hydrolyzing β-d-(1,6) glycosidic linkages. Notably, it exhibited a preference for d-glucopyranosyl (d-Glcp) over d-galactopyranosyl (d-Galp) and d-fructofuranosyl (d-Fruf) at the reducing end of the investigated disaccharides. In addition, we determined the high resolution crystal structure of BD-β-Gal, thus providing the first structural characterization of a GH154 enzyme. Surprisingly, this revealed an (α/α)6 topology,...
Source: New Biotechnology - January 1, 2024 Category: Biotechnology Authors: Lisanne Hameleers Tjaard Pijning Brandon B Gray R égis Fauré Edita Jurak Source Type: research
Co-culture platform for tuning of cancer receptor density allows for evaluation of bispecific immune cell engagers
N Biotechnol. 2023 Dec 28:S1871-6784(23)00080-8. doi: 10.1016/j.nbt.2023.12.012. Online ahead of print.ABSTRACTCancer immunotherapy, where a patient's immune system is harnessed to eradicate cancer cells selectively, is a leading strategy for cancer treatment. However, successes with immune checkpoint inhibitors (ICI) are hampered by reported systemic and organ-specific toxicities and by two-thirds of the patients being non-responders or subsequently acquiring resistance to approved ICIs. Hence substantial efforts are invested in discovering novel targeted immunotherapies aimed at reduced side-effects and improved potency....
Source: New Biotechnology - December 30, 2023 Category: Biotechnology Authors: Aman Mebrahtu Gustav Aniander Alessandro Mega Mona Moradi Barzadd Niklas Berndt Thal én Lindvi Gudmundsdotter Eva Backstr öm Rydin Anna Sandegren Fredrik Y Frejd Johan Rockberg Source Type: research
Post-translational secretion stress regulation in Bacillus subtilis is controlled by intra- and extracellular proteases
N Biotechnol. 2023 Dec 27;79:71-81. doi: 10.1016/j.nbt.2023.12.009. Online ahead of print.ABSTRACTThe Gram-positive bacterium Bacillus subtilis is a prolific producer of industrial enzymes that are effectively harvested from the fermentation broth. However, the high capacity of B. subtilis for protein secretion has so far not been exploited to the full due to particular bottlenecks, including product degradation by extracellular proteases and counterproductive secretion stress responses. To unlock the Bacillus secretion pathway for difficult-to-produce proteins, various cellular interventions have been explored, including ...
Source: New Biotechnology - December 29, 2023 Category: Biotechnology Authors: Ay şegül Öktem Dicky A Pranoto Jan Maarten van Dijl Source Type: research
Biorefinery of brewery spent grain to obtain bioproducts with high value-added in the market
N Biotechnol. 2023 Dec 27:S1871-6784(23)00078-X. doi: 10.1016/j.nbt.2023.12.010. Online ahead of print.ABSTRACTThe brewery industry is under economic and environmental pressure to minimize residual management costs, particularly brewery spent grain (BSG), which accounts for 80-85% (w/w) of the total by-products generated. BSG is a lignocellulosic material primarily composed of carbohydrates, proteins and lipids. Developing a biorefinery model for conversion of BSG into value-added products is a plausible idea. Previous work optimized the pretreatment of BSG with the ionic liquid [N1112OH][Gly] and further release of fermen...
Source: New Biotechnology - December 29, 2023 Category: Biotechnology Authors: David Outeiri ño Iv án Costa-Trigo Aida Ochogavias Ricardo Pinheiro de Souza Oliveira Nelson P érez Guerra Jos é Manuel Salgado Jos é Manuel Domínguez Source Type: research
In pursuit of a minimal CHO genome: Establishment of large-scale genome deletions
N Biotechnol. 2023 Dec 26:S1871-6784(23)00075-4. doi: 10.1016/j.nbt.2023.12.007. Online ahead of print.ABSTRACTChinese hamster ovary (CHO) cells are the most commonly used mammalian cell line for the production of complex therapeutic glycoproteins. As CHO cells have evolved as part of a multicellular organism, they harbor many cellular functions irrelevant for their application as production hosts in industrial bioprocesses. Consequently, CHO cells have been the target for numerous genetic engineering efforts in the past, but a tailored host cell chassis holistically optimized for its specific task in a bioreactor is still...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Linus Wei ß Hannah Fahrion Nikolas Zeh Nadja Raab Benjamin Lindner Simon Fischer Kerstin Otte Source Type: research
Inefficient transcription is a production bottleneck for artificial therapeutic BiTE ® proteins
N Biotechnol. 2023 Dec 26;79:91-99. doi: 10.1016/j.nbt.2023.12.008. Online ahead of print.ABSTRACTAntibodies are potent biopharmaceuticals used to treat severe diseases, including cancers. During the past decade, more complex modalities have been developed including bispecific T-cell engager (BiTE®) molecules, e.g. by Amgen. However, non-natural and complex molecule formats often prove to be difficult-to-express (DTE), which is the case for BiTE® molecules. Due to the growing importance of multispecific modalities such as half-life extended (HLE) BiTE® and HLE dual-targeting bispecific T-cell engager (dBiTE) molecules, ...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Madina Burkhart Selina Goetz Benedikt Greck Anika Menthe Ruediger Neef Kerstin Otte Source Type: research
In pursuit of a minimal CHO genome: Establishment of large-scale genome deletions
N Biotechnol. 2023 Dec 26:S1871-6784(23)00075-4. doi: 10.1016/j.nbt.2023.12.007. Online ahead of print.ABSTRACTChinese hamster ovary (CHO) cells are the most commonly used mammalian cell line for the production of complex therapeutic glycoproteins. As CHO cells have evolved as part of a multicellular organism, they harbor many cellular functions irrelevant for their application as production hosts in industrial bioprocesses. Consequently, CHO cells have been the target for numerous genetic engineering efforts in the past, but a tailored host cell chassis holistically optimized for its specific task in a bioreactor is still...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Linus Wei ß Hannah Fahrion Nikolas Zeh Nadja Raab Benjamin Lindner Simon Fischer Kerstin Otte Source Type: research
Inefficient transcription is a production bottleneck for artificial therapeutic BiTE ® proteins
N Biotechnol. 2023 Dec 26:S1871-6784(23)00076-6. doi: 10.1016/j.nbt.2023.12.008. Online ahead of print.ABSTRACTAntibodies are potent biopharmaceuticals used to treat severe diseases, including cancers. During the past decade, more complex modalities have been developed including bispecific T-cell engager (BiTE®) molecules, e.g. by Amgen. However, non-natural and complex molecule formats often prove to be difficult-to-express (DTE), which is the case for BiTE® molecules. Due to the growing importance of multispecific modalities such as half-life extended (HLE) BiTE® and HLE dual-targeting bispecific T-cell engager (dBiTE...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Madina Burkhart Selina Goetz Benedikt Greck Anika Menthe Ruediger Neef Kerstin Otte Source Type: research
In pursuit of a minimal CHO genome: Establishment of large-scale genome deletions
N Biotechnol. 2023 Dec 26:S1871-6784(23)00075-4. doi: 10.1016/j.nbt.2023.12.007. Online ahead of print.ABSTRACTChinese hamster ovary (CHO) cells are the most commonly used mammalian cell line for the production of complex therapeutic glycoproteins. As CHO cells have evolved as part of a multicellular organism, they harbor many cellular functions irrelevant for their application as production hosts in industrial bioprocesses. Consequently, CHO cells have been the target for numerous genetic engineering efforts in the past, but a tailored host cell chassis holistically optimized for its specific task in a bioreactor is still...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Linus Wei ß Hannah Fahrion Nikolas Zeh Nadja Raab Benjamin Lindner Simon Fischer Kerstin Otte Source Type: research
Inefficient transcription is a production bottleneck for artificial therapeutic BiTE ® proteins
N Biotechnol. 2023 Dec 26:S1871-6784(23)00076-6. doi: 10.1016/j.nbt.2023.12.008. Online ahead of print.ABSTRACTAntibodies are potent biopharmaceuticals used to treat severe diseases, including cancers. During the past decade, more complex modalities have been developed including bispecific T-cell engager (BiTE®) molecules, e.g. by Amgen. However, non-natural and complex molecule formats often prove to be difficult-to-express (DTE), which is the case for BiTE® molecules. Due to the growing importance of multispecific modalities such as half-life extended (HLE) BiTE® and HLE dual-targeting bispecific T-cell engager (dBiTE...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Madina Burkhart Selina Goetz Benedikt Greck Anika Menthe Ruediger Neef Kerstin Otte Source Type: research
In pursuit of a minimal CHO genome: Establishment of large-scale genome deletions
N Biotechnol. 2023 Dec 26:S1871-6784(23)00075-4. doi: 10.1016/j.nbt.2023.12.007. Online ahead of print.ABSTRACTChinese hamster ovary (CHO) cells are the most commonly used mammalian cell line for the production of complex therapeutic glycoproteins. As CHO cells have evolved as part of a multicellular organism, they harbor many cellular functions irrelevant for their application as production hosts in industrial bioprocesses. Consequently, CHO cells have been the target for numerous genetic engineering efforts in the past, but a tailored host cell chassis holistically optimized for its specific task in a bioreactor is still...
Source: New Biotechnology - December 28, 2023 Category: Biotechnology Authors: Tobias Jerabek Linus Wei ß Hannah Fahrion Nikolas Zeh Nadja Raab Benjamin Lindner Simon Fischer Kerstin Otte Source Type: research
